SCHEMBL1382259

SCHEMBL1382259

Cc1c(-c2ccncn2)sc(NC(N)=O)c1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 4/20 0.40
LMNA P02545 1/20 0.40
IKBKB O14920 3/20 0.39
AIP O00170 1/20 0.39
SGTA O43765 1/20 0.39
TOMM70 O94826 1/20 0.39
STIP1 P31948 1/20 0.39
PPP5C P53041 1/20 0.39
FKBP4 Q02790 1/20 0.39
PPID Q08752 1/20 0.39
FKBP5 Q13451 1/20 0.39
FKBP8 Q14318 1/20 0.39
TOMM34 Q15785 1/20 0.39
DNAJC7 Q99615 1/20 0.39
AIPL1 Q9NZN9 1/20 0.39
STUB1 Q9UNE7 1/20 0.39
RAB9A P51151 5/20 0.39
MAPT P10636 5/20 0.39
NPC1 O15118 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382805 0.84 ALDH1A1 (0.46) ALDH1A1KDM4ELMNAIKBKBAIP
SCHEMBL4092649 0.82 IKBKB (0.44) ALDH1A1KDM4ELMNAIKBKBAIP
SCHEMBL1381499 0.81 RAB9A (0.41) ALDH1A1KDM4ELMNAIKBKBAIP
SCHEMBL1382754 0.77 CHEK1 (0.43) ALDH1A1KDM4ELMNAIKBKBAIP
SCHEMBL1382683 0.73 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAIKBKBRAB9A
SCHEMBL1382766 0.73 KIF11 (0.49) ALDH1A1KDM4ELMNAIKBKBAIP
SCHEMBL1382924 0.72 ALDH1A1 (0.43) ALDH1A1KDM4ELMNAIKBKBAIP
SCHEMBL1383438 0.72 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAIKBKBAIP
SCHEMBL1928166 0.71 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAIKBKBRAB9A
SCHEMBL1384699 0.71 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAIKBKBAIP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4812999-B2 2011-11-09 JP claimed
US-20090181962-A1 Substituted thiophene compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2009-07-16 US claimed
CN-1243747-C Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 ASTRAZENECA AB (SE) 2006-03-01 CN claimed
EP-1261600-B1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2004-05-06 EP claimed
CN-1425012-A Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 ASTRAZENECA AB (SE) 2003-06-18 CN claimed
EP-1261600-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 AstraZeneca AB (SE) 2002-12-04 EP claimed
US-20020107252-A1 Novel Compounds ASTRAZENECA AB (SE) 2002-08-08 US claimed
WO-2001058890-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2001-08-16 WO claimed
US-20090181962-A1 Substituted thiophene compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2009-07-16 US disclosed
US-7358376-B2 Substituted Thiophene compounds ASTRAZENECA AB (SE) 2008-04-15 US disclosed
CN-1243747-C Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 ASTRAZENECA AB (SE) 2006-03-01 CN disclosed
US-20050075341-A1 Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury PHARMACIA CORPORATION (US) 2005-04-07 US disclosed
WO-2005009354-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY PHARMACIA CORPORATION (US) 2005-02-03 WO disclosed
EP-1261600-B1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2004-05-06 EP disclosed
CN-1425012-A Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 ASTRAZENECA AB (SE) 2003-06-18 CN disclosed
EP-1261600-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 AstraZeneca AB (SE) 2002-12-04 EP disclosed
US-20020107252-A1 Novel Compounds ASTRAZENECA AB (SE) 2002-08-08 US disclosed
WO-2001058890-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181962-A1 Substituted thiophene compounds ABCG2, SULT1E1, TPMT ALDH1A1 165/4885KDM4E 652/4885LMNA 4337/4885
US-20020107252-A1 Novel Compounds UGT1A1, CYP1B1, CYP1A1 ALDH1A1 35/4885KDM4E 1332/4885LMNA 2892/4885
US-20050075341-A1 Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury IKBKE, IKBKG, IKBKB ALDH1A1 3943/4885KDM4E 3226/4885LMNA 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.